Credit Suisse Upgrades Esperion Therapeutics Inc to Neutral

Brokerage firm Credit Suisse Upgrades its rating on Esperion Therapeutics Inc(ESPR). The shares have been rated Neutral. Previously, the analysts had a Underperform rating on the shares. The rating by the stock financial advisor at Credit Suisse was issued on Mar 20, 2017 in a research report to their Investors and Clients.

In a different note, On Mar 20, 2017, Needham said it Maintains its rating on Esperion Therapeutics Inc. According to the research note, Needham Raises the price target to $58 per share from a prior target of $25. The shares have been rated ‘Strong Buy’ by the firm. On Feb 28, 2017, Citigroup said it Upgrades its rating on Esperion Therapeutics Inc. The shares have been rated ‘Buy’ by the firm.

Esperion Therapeutics Inc (ESPR) shares turned negative on Wednesdays trading session with the shares closing down -0.04 points or -0.10% at a volume of 52,55,021. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $41.6999. The peak price level was also seen at $41.6999 while the days lowest was $37.26. Finally the shares closed at $39.01. The 52-week high of the shares is $48.21 while the 52-week low is $9.4. According to the latest information available, the market cap of the company is $880 M.

Esperion Therapeutics Inc(ESPR) last announced its earnings results on Feb 22, 2017 for Fiscal Year 2016 and Q4.Earnings per share were $-1.29. Analysts had estimated an EPS of $-1.24.

Several Insider Transactions has been reported to the SEC. On Nov 3, 2016, Narendra D. Lalwani (COO) purchased 5,000 shares at $9.93 per share price.Also, On Jul 7, 2016, Mark E Mcgovern (director) purchased 5,000 shares at $10.00 per share price.On May 5, 2016, Timothy M Mayleben (CEO) purchased 7,000 shares at $14.85 per share price, according to the Form-4 filing with the securities and exchange commission.

Esperion Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Company’s primary activities include conducting research and development activities including nonclinical preclinical and clinical testing performing business and financial planning recruiting personnel and raising capital. ETC-1002 the Company’s lead product candidate is an orally available once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.

Add Comment